Mitochondrial DNA Haplogroups and Susceptibility to Prostate Cancer in a Colombian Population

Table 3

Frequencies (%) of mitochondrial DNA haplogroups in patients and controls.

Haplogroup	Patients with prostate cancer; 𝑛=168	Control group; 𝑛=140	P value^1
A	41.1 (𝑛=69)	42.1 (𝑛=59)	0.84
B	22.0 (𝑛=37)	21.4 (𝑛=30)	0.89
C	11.9 (𝑛=20)	11.4 (𝑛=16)	0.89
D	6.0 (𝑛=10)	10.0 (𝑛=14)	0.18
H	5.5 (𝑛=9)	8.0 (𝑛=11)	0.37
HV	1.9 (𝑛=3)	0.8 (𝑛=1)	0.40
L	6.6 (𝑛=11)	2.1 (𝑛=3)	0.06
J	0.7 (𝑛=1)	0.0 (𝑛=0)	0.36
K	0.0 (𝑛=0)	0.7 (𝑛=1)	0.27
M	0.6 (𝑛=1)	0.0 (𝑛=0)	0.36
N	0.0 (𝑛=0)	1.4 (𝑛=2)	0.12
T	1.9 (𝑛=3)	0.0 (𝑛=0)	0.11
U	2.4 (𝑛=4)	2.1 (𝑛=3)	0.88

¹𝑃 value: Pearson chi-square or Fisher’s exact tests.